Braveheart Bio (BRVE) Files for $300 Million IPO Ahead of Phase 3 Therapy
Clinical-stage biotech aims to improve upon first-generation heart therapies with a next-generation cardiac myosin inhibitor entering Phase 3...
106 Views
IPO Databook: Braveheart Bio (BRVE US) - Jul 2026
Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious...
152 Views
Braveheart Bio (BRVE US): Synthetic Expert Call Transcript (31 Jul 2026)
BHB-1893’s primary commercial differentiator is its shallow left ventricular ejection fraction (LVEF) dose-response curve, which showed a minimal...
121 Views
Braveheart Bio Inc. (BRVE): Phase 3 Hypertrophic Cardiomyopathy Biotech Sets Terms for IPO
​Braveheart's lead asset BHB-1893 shows promise for treating HCM, with Fidelity's $75 million investment and positive clinical data boosting...
127 Views